XinGaoMD

Oncology • Boston, MA

Genitourinary Oncology

Physician

Join to view full profile

Dr. Gao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gao's full profile

Already have an account?

Office
55 Fruit Street
Boston, MA 02114

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
Brigham and Women's HospitalResidency, Internal Medicine, 2012 - 2015
Harvard Medical SchoolClass of 2012

Certifications & Licensure

MA State Medical License 2012 - 2026
NH State Medical License 2024 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2021 May 21
Withdrawn
Phase 2
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Start of enrollment: 2022 Mar 29
Recruiting
Phase 1, Phase 2
Roles: Contact
Precision-Based Genomics in Prostate Cancer Start of enrollment: 2021 Sep 14
Recruiting
Roles: Contact
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies Start of enrollment: 2019 Oct 30
Recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma Start of enrollment: 2023 Aug 24
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Eric J Miller, Tracy L Rose, Benjamin L Maughan, Matthew I Milowsky, Mehmet A Bilen
Cancer. 2024-05-01
24 citations
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Rhonda Bitting
Journal of the National Comprehensive Cancer Network. 2024-04-01
Targeting Androgen Receptor Mutations in Metastatic Castration-Resistant Prostate Cancer with a Novel Androgen Biosynthesis Inhibitor.
Xin Gao
NEJM Evidence. 2024-01-01

Journal Articles

Combination Immunotherapy and Targeted Therapy: Will New Combinations Raise the Tail of the Survival Curve?
Gao X, Kidney Cancer Journal, 10/7/2018

Press Mentions

Enzalutamide Survival Benefit in Metastatic Prostate Cancer Persists Beyond Five YearsJune 20th, 2022
Diving Deeper into Benefit of Avelumab Maintenance in Bladder CancerJune 24th, 2021
Weymouth Kidney Cancer Victim’s Memory Fuels MGH Research FundraiserNovember 13th, 2019

Professional Memberships

Other Languages

Chinese (Mandarin)